202 related articles for article (PubMed ID: 28406092)
1. Safety of azathioprine and 6-mercaptopurine in patients with inflammatory bowel disease naïve to thiopurine treatment
.
Alaish R; Lundgren D; Suhr OB; Werner M; Karling P
Int J Clin Pharmacol Ther; 2017 Jul; 55(7):594-600. PubMed ID: 28406092
[TBL] [Abstract][Full Text] [Related]
2. More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing.
Broekman MMTJ; Coenen MJH; van Marrewijk CJ; Wanten GJA; Wong DR; Verbeek ALM; Klungel OH; Hooymans PM; Guchelaar HJ; Scheffer H; Derijks LJJ; de Jong DJ;
Inflamm Bowel Dis; 2017 Oct; 23(10):1873-1881. PubMed ID: 28644183
[TBL] [Abstract][Full Text] [Related]
3. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
Dubinsky MC; Feldman EJ; Abreu MT; Targan SR; Vasiliauskas EA
Am J Gastroenterol; 2003 May; 98(5):1058-63. PubMed ID: 12809828
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of tolerance to mercaptopurine in patients with inflammatory bowel disease and gastrointestinal intolerance to azathioprine.
Bastida G; Alvarez-Sotomayor D; Aguas M; Iborra M; Del Hoyo J; Béjar-Serrano S; Garrido-Marín A; Valero-Pérez E; Nos P
Gastroenterol Hepatol; 2024 May; 47(5):473-480. PubMed ID: 38072359
[TBL] [Abstract][Full Text] [Related]
5. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
Coenen MJ; de Jong DJ; van Marrewijk CJ; Derijks LJ; Vermeulen SH; Wong DR; Klungel OH; Verbeek AL; Hooymans PM; Peters WH; te Morsche RH; Newman WG; Scheffer H; Guchelaar HJ; Franke B;
Gastroenterology; 2015 Oct; 149(4):907-17.e7. PubMed ID: 26072396
[TBL] [Abstract][Full Text] [Related]
6. Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center.
Banerjee S; Bishop WP
J Pediatr Gastroenterol Nutr; 2006 Sep; 43(3):324-30. PubMed ID: 16954954
[TBL] [Abstract][Full Text] [Related]
7. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD.
Kakuta Y; Naito T; Onodera M; Kuroha M; Kimura T; Shiga H; Endo K; Negoro K; Kinouchi Y; Shimosegawa T
Pharmacogenomics J; 2016 Jun; 16(3):280-5. PubMed ID: 26076924
[TBL] [Abstract][Full Text] [Related]
8. Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger.
Grossman AB; Noble AJ; Mamula P; Baldassano RN
Inflamm Bowel Dis; 2008 Jun; 14(6):750-5. PubMed ID: 18266236
[TBL] [Abstract][Full Text] [Related]
9. Clinical Value of Mercaptopurine After Failing Azathioprine Therapy in Patients With Inflammatory Bowel Disease.
Meijer B; Seinen ML; Leijte NN; Mulder CJ; van Bodegraven AA; de Boer NK
Ther Drug Monit; 2016 Aug; 38(4):463-70. PubMed ID: 27158876
[TBL] [Abstract][Full Text] [Related]
10. Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients.
Shaye OA; Yadegari M; Abreu MT; Poordad F; Simon K; Martin P; Papadakis KA; Ippoliti A; Vasiliauskas E; Tran TT
Am J Gastroenterol; 2007 Nov; 102(11):2488-94. PubMed ID: 17764490
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of low dose azathioprine/6-mercaptopurine in patients with inflammatory bowel disease.
Kim DU; Kim YH; Kim BJ; Chang DK; Son HJ; Rhee PL; Kim JJ; Rhee JC
Hepatogastroenterology; 2009; 56(94-95):1395-402. PubMed ID: 19950798
[TBL] [Abstract][Full Text] [Related]
12. [The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease].
Kim JH; Cheon JH; Kim WH
Korean J Gastroenterol; 2008 May; 51(5):291-7. PubMed ID: 18516013
[TBL] [Abstract][Full Text] [Related]
13. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
Gómez-García M; Cabello-Tapia MJ; Sánchez-Capilla AD; De Teresa-Galván J; Redondo-Cerezo E
World J Gastroenterol; 2013 Aug; 19(30):4877-86. PubMed ID: 23946592
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review.
Gisbert JP; Gomollón F
Am J Gastroenterol; 2008 Jul; 103(7):1783-800. PubMed ID: 18557712
[TBL] [Abstract][Full Text] [Related]
15. The drug-survival of low-dose thioguanine in patients with inflammatory bowel disease: a retrospective observational study.
Gensmyr-Singer H; Werner M; Karling P
Therap Adv Gastroenterol; 2024; 17():17562848241228064. PubMed ID: 38384282
[TBL] [Abstract][Full Text] [Related]
16. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
[TBL] [Abstract][Full Text] [Related]
17. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.
Derijks LJ; de Jong DJ; Gilissen LP; Engels LG; Hooymans PM; Jansen JB; Mulder CJ
Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):63-7. PubMed ID: 12544696
[TBL] [Abstract][Full Text] [Related]
18. Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism.
Shih DQ; Nguyen M; Zheng L; Ibanez P; Mei L; Kwan LY; Bradford K; Ting C; Targan SR; Vasiliauskas EA
Aliment Pharmacol Ther; 2012 Sep; 36(5):449-58. PubMed ID: 22784257
[TBL] [Abstract][Full Text] [Related]
19. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines.
Dotan I; Werner L; Vigodman S; Agarwal S; Pfeffer J; Horowitz N; Malter L; Abreu M; Ullman T; Guzner-Gur H; Halpern Z; Mayer L
Inflamm Bowel Dis; 2012 Feb; 18(2):261-8. PubMed ID: 21438101
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine.
Wahed M; Louis-Auguste JR; Baxter LM; Limdi JK; McCartney SA; Lindsay JO; Bloom SL
Aliment Pharmacol Ther; 2009 Sep; 30(6):614-20. PubMed ID: 19552632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
